Screener
Janux Therapeutics JANX Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Janux Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The source filing: Janux Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:18 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338078
FAQ
- What is Janux Therapeutics's shares (diluted)?
- Janux Therapeutics (JANX) reported shares (diluted) of 62.9M in Q2 2026.
- How has Janux Therapeutics's shares (diluted) changed year-over-year?
- Janux Therapeutics's shares (diluted) increased by 1.7% year-over-year, from 61.9M to 62.9M.
- What is the long-term trend for Janux Therapeutics's shares (diluted)?
- Over 4 years (2021 to 2025), Janux Therapeutics's shares (diluted) has grown at a 34.4% compound annual growth rate (CAGR), from 75.8M to 247.7M.
- What does shares (diluted) mean?
- The weighted-average shares outstanding plus all potentially dilutive shares from stock options, RSUs, convertible securities, and warrants, using the treasury stock method.
Ask your AI about Janux Therapeutics's shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude